

14<sup>th</sup> December, 2022

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Torrent Pharmaceuticals Ltd enters into co-marketing partnership with Boehringer Ingelheim India Private Limited to co- market its anti-diabetic drug and its fixed dose combinations in India**

---

A press release issued by the Company with respect to captioned subject is attached for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN  
MAHESHKUMAR TRIVEDI  
AR TRIVEDI

Digitally signed by  
CHINTAN  
MAHESHKUMAR TRIVEDI  
Date: 2022.12.14  
15:33:04 +05'30'

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

Encl : A/a

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

## MEDIA RELEASE



### **Torrent Pharmaceuticals Ltd enters into co-marketing partnership with Boehringer Ingelheim India Private Limited; to co-market its anti-diabetic drug and its fixed dose combinations in India**

**Ahmedabad, 14<sup>th</sup> December, 2022** Torrent Pharmaceuticals Ltd ("Torrent") has entered into a strategic alliance with Boehringer Ingelheim India Private Limited ("BI India") to co-market Cospiaq® (Empagliflozin), Cospiaq Met™ (Empagliflozin+ Metformin) and Xilingio® (Empagliflozin+ Linagliptin) in India.

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. Further, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.

As per International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2022 data, the Indian diabetes medications market is valued at INR 16,516 crore, growing at 8.6% CAGR over the last 4 years. The market for SGLT-2 Inhibitors is valued at 1,927 Crores and the SGLT-2 Inhibitors are growing faster than the diabetes market faster at 33% CAGR over the same time period.

Aman Mehta, Director, Torrent Pharmaceuticals Ltd. said, "Torrent is delighted to enter into a strategic partnership with Boehringer Ingelheim India to address the dual challenges of type-2 diabetes and heart failure (both preserved and reduced ejection fractions) in India. I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall Diabetes and Cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian Pharmaceutical Market."

Vani Manja, Managing Director, Boehringer Ingelheim India said, "We are pleased to partner with Torrent for the sales and co-marketing of Empagliflozin and its combinations. Our collaboration with Torrent reaffirms our commitment towards enabling improved access to innovative medicine in India. We believe that the coming together of the healthcare ecosystem is key to address unmet needs of patients."

#### **About Torrent Pharmaceuticals Ltd:**

Torrent Pharma, with annual revenue of more than Rs 8,500 crores, is the flagship Company of the Torrent Group, with group revenue of more than Rs 22,500 crores. It is ranked 8th in the Indian

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

#### **TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, [www.torrentpharma.com](http://www.torrentpharma.com)

## **MEDIA RELEASE**



Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Vitamins Minerals Nutritionals (VMN).

It is a specialty-focused company with 74%+ of its revenue in India from chronic & sub- chronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines. Torrent has 7 manufacturing facilities, of which 4 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 800+ scientists.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

### **TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, [www.torrentpharma.com](http://www.torrentpharma.com)